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Neuroﬁbromatosis type 1 (NF1) demonstrates phenotypic overlap with Noonan syndrome (NS) in some patients,
which results in the so-called neuroﬁbromatosis-Noonan syndrome (NFNS). From a genetic point of view, NFNS
is a poorly understood condition, and controversy remains as to whether it represents a variable manifestation of
either NF1 or NS or is a distinct clinical entity. To answer this question, we screened a cohort with clinically well-
characterized NFNS for mutations in the entire coding sequence of the NF1 and PTPN11 genes. Heterozygous
NF1 defects were identiﬁed in 16 of the 17 unrelated subjects included in the study, which provides evidence that
mutations in NF1 represent the major molecular event underlying this condition. Lesions included nonsense mu-
tations, out-of-frame deletions, missense changes, small inframe deletions, and one large multiexon deletion. Re-
markably, a high prevalence of inframe defects affecting exons 24 and 25, which encode a portion of the GAP-
related domain of the protein, was observed. On the other hand, no defect in PTPN11 was observed, and no lesion
affecting exons 11–27 of the NF1 gene was identiﬁed in 100 PTPN11 mutation-negative subjects with NS, which
provides further evidence that NFNS and NS are genetically distinct disorders. These results support the view that
NFNS represents a variant of NF1 and is caused by mutations of the NF1 gene, some of which have been dem-
onstrated to cause classic NF1 in other individuals.
The so-called neuroﬁbromatosis-Noonan syndrome
(NFNS [MIM 601321]) is a peculiar clinical association,
ﬁrst noted in 1985 by Allanson and colleagues (1985),
who described subjects with features of both neuroﬁbro-
matosis type 1 (NF1 [MIM 162200]) and Noonan syn-
drome (NS [MIM 163950]) (Opitz and Weaver 1985).
Since that report, a number of NFNS cases, including
a few families transmitting the trait, have been docu-
mented (Kaplan and Rosenblatt 1985; Mendez 1985;
Saul 1985; Meinecke 1987; Quattrin et al. 1987; Shuper
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et al. 1987; Abuelo andMeryash 1988; Stern et al. 1992;
Colley et al. 1996).
It has been long speculated whether NFNS is a variant
of either NF1 (Riccardi 1992) or NS (Allanson 1987),
there is a chance association, or they are distinct dis-
orders (Opitz and Weaver 1985; Colley et al. 1996; Ca-
rey 1998). Colley et al. (1996) and Bahuau et al. (1996,
1998) documented independent segregation of NF1 and
NS traits in two families. Stern et al. (1992) and Colley
et al. (1996) reported a few families in which only a
fraction of affected members with NF1 exhibited some
NS features. Carey et al. (1997) ﬁrst reported a two-
generation family in which the NFNS trait cosegregated
with a mutation within the NF1 gene, the gene respon-
sible for all cases of NF1 (Xu et al. 1990). Subsequently,
Baralle et al. (2003) examined the NF1 gene in six sub-
jects with NFNS and found mutations in two cases. Very
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Table 1
Clinical Features of 22 Subjects with NFNS
CHARACTERISTICS
FINDINGS FOR
NFNS1 62c NFNS3 NFNS4 69c
Family 6 Family 7
NFNS6a NFNS6b NFNS6c NFNS7a NFNS7b NFNS7c
Age (in years) at observation 9 6.5 6 2.2 8 7 11 41 18 13 47
Sex M F M F M F M F F M M
NF1 features:
CLS           
Neuroﬁbromas   (1)         
Plexiform neuroﬁbromas           
Axillary freckling           
Lisch nodules     NE      
Optic gliomas BIL MON *     NE   NE
Other MRI ﬁndings UBOs UBOs * UBOs NE   NE UBOs, SM UBOs NE
Mental retardation     Mild      
Learning difﬁculties    NV       
Scoliosis           
Other tumors       NE NBL   
NS features:
Short stature      Mild     
Macrocephaly           
Cardiac defect    PVS  PVS   MVP  
Hypertelorism           
Downslanting palpebral ﬁssures           
Ptosis           
Malar hypoplasia           
Epicanthic folds           
Other facial dysmorphisms TL TL, FNB  TL HP, MS, LE, MO    TL  
Low posterior hairline           
Short/broad/webbed neck           
Low-set posteriorly rotated ears           
Pectus/thoracic abnormality           
Cubitus valgus           
Cryptorchidism      
Urinary system abnormality           
Additional features HN  HYP, HJ   Myopia     
Family history S S S S S FA FA FA FA FA FA
NOTE.—Spsporadic; FApfamilial; a plus sign ()ppresent; a minus sign ()pabsent; NEpnot evaluated; NVpnot evaluable; BILpbilateral; MONpmono-
lateral. Craniofacial features: HPphigh arched palate; MOpmalocclusion; TLpthick lips; FNBpﬂat nasal bridge; LEplarge ears. Ectodermal features: KPpkera-
tosis pilaris (face); HNphairy nevus; Epeczema; SLEpsparse lateral eyebrows. Cardiac defects: ASDpatrial septal defect (ostium secundum); Aparrhythmia
(right-branch block); MVTpmitral valve thickening; MVPpmitral valve prolapse. Other features: an asterisk (*)pmild thickening of the optic nerves; SMpthoracic
syringomyelia; NBLpneuroblastoma; SDpsensorineural deafness; CDpconductive deafness, SEpseizures; RBApretarded bone age; HYPphypotonia; HJphy-
perextensible joints; Hphyperactivity; PPDppostaxial polydactyly of hands; MSpmacrostomia; RCprenal cyst; RKpRokitansky.
a With dysplastic leaﬂets.
recently, Bertola et al. (2005) reported a patient with
NF1 and NS features who carried a heterozygous mu-
tation in both NF1 and PTPN11 (MIM 176876), the
latter of which is responsible for half of the cases of NS
(Tartaglia et al. 2001), providing the molecular evidence
for concurrence of both disorders in one individual.
However, from a genetic point of view, NFNS still re-
mains a poorly understood disorder.
To delineate the genetic cause of NFNS, we screened
a well-characterized NFNS cohort for mutations affect-
ing the NF1 and PTPN11 genes. Included in the study
were 14 unrelated Italians with sporadicNFNS and three
families transmitting the trait. All subjects were evalu-
ated by clinical dysmorphologists experienced with both
NF1 and NS (G.Z., A.B., C.D., and B.D.). For each pa-
tient, clinical assessment included family history; physi-
cal, anthropometric, neurological, and cardiac evalua-
tion (including chest x-ray, electrocardiogram, and 2-
dimensional and color Doppler echocardiography); renal
ultrasonography; and radiological and magnetic reso-
nance imaging (MRI) studies. The phenotype was eval-
uated through accurate clinical examination for NS fa-
cial and other dysmorphisms, such as hypertelorism (in-
terpupillary distance 12 SD), ptosis (abnormally low lid
position), downslanting palpebral ﬁssures, low-set and
posteriorly rotated ears, short neck, low posterior hair
line, and thoracic and other skeletal anomalies. NF1was
diagnosed on the presence of features ﬁtting the NF1
diagnostic criteria (Stumpf et al. 1988; Gutmann et al.
1997), whereas, for diagnosis of NS, the criteria intro-
duced by van der Burgt et al. (1994) and discussed by
Jongmans et al. (2005) were used. The clinical features
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FINDINGS FOR
TOTALNFNS8 NFNS9 NFNS10 NFNS11 NFNS12 70c 128
Family 15
NFNS16 NFNS17NFNS15a NFNS15b
2.2 6 4 40 9.5 38 10 17.7 45 7 12
M F F F F F M M M M M 12M, 10F
           22/22
           9/22
      (1)      1/22
           16/22
     NE     5 12/20
NE NE NE  NE NE   NE   4/14
NE NE NE UBOs NE NE UBOs  NE UBOs UBOs 9/13
           4/22
NV           11/20
           9/22
           1/21
           10/22
           14/22
PVS  ASD  PVSa MVT A     7/22
           20/22
           18/22
           15/22
           5/22
           12/22
TL  TL   HP TL TL TL SLE 
           17/22
           14/22
           22/22
           11/22
           7/22
      1/12
   RK   RC     2/22
H E SD  KP, PPD,   SE, BIL   
SD, RBA CD
S S S S S S S FA FA S S 13 S; 3 FA
of the study population are summarized in table 1 and
are shown in ﬁgure 1. Cafe´-au-lait spots (CLSs) and low-
set posteriorly rotated ears were observed in all sub-
jects. CLSs were numerous and stochastically dispersed
but variable in number (from 15 to 59) and size (from
pointlike to ) among different-aged patients.8 # 2.5 cm
Among the NF1 features, a variable number (1–30) of
neuroﬁbromas and Crowe sign (freckling of axillary and
inguinal regions) were present in 41% and 73% of sub-
jects, respectively. Lisch nodules were detected in 60%
of patients, whereas optic gliomas or otherMRI ﬁndings,
such as unidentiﬁed bright objects (UBOs), were found
in 28% and 69%, respectively. A single plexiform neu-
roﬁbroma was observed in one patient. Among the NS
features, a variable combination of facial dysmorphisms
was observed in all subjects. Short stature and congenital
heart defect (CHD) were present in 45% and 32% of
the subjects, respectively. In the latter, pulmonary valve
stenosis (PVS) was the prevailing defect (50% of cases).
Short and/or webbed neck and thoracic abnormalities
were also common, present in 64% and 50% of subjects,
respectively. Among the features common to both con-
ditions, macrocephaly and scoliosis were observed in
64% and 41% of patients, respectively, whereas mental
retardation or learning difﬁculties were documented in
half of all patients. All patients fulﬁlled the National
Institutes of Health Consensus Criteria for the diagnosis
of NF1, except for the four youngest patients (individ-
uals NFNS-3, NFNS-4, NFNS-8, and NFNS-10), who
presented with only one NF1 criteria, almost certainly
because of their young age. In particular, patient NFNS-
3, aged 6 years, showed 160 CLSs and mild thickening
of the optic nerves on MRI investigation; patient NFNS-
4, aged 2.2 years, presented with 120 CLSs and UBOs;
whereas patients NFNS-8 and NFNS-10 presented with
115 CLSs at age 2.2 and 4 years, respectively.
Genomic DNA was isolated from peripheral-blood
lymphocytes by phenolchloroform extraction and etha-
nol precipitation. The entire coding sequence and ﬂank-
ing intronic portions of the NF1 and PTPN11 genes
were screened by denaturing high-performance liquid
chromatography (DHPLC) analysis, by use of a 3100 or
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Figure 1 Facial characteristics and other clinical features of study individuals with NFNS
3500HT WAVE DNA fragment analysis system (Trans-
genomic). PCR settings, amplicons length, and resolution
temperatures for DHPLC analysis were reported else-
where (Tartaglia et al. 2002, 2004a; De Luca et al. 2003,
2004). Bidirectional sequencing of puriﬁed PCR prod-
ucts (Qiagen) was performed using the ABI BigDye Ter-
minator Sequencing Kit v.1.1 (Applied Biosystems) and
an ABI 3700 Capillary Array Sequencer or ABI Prism
3100 Genetic Analyzer (Applied Biosystems).
No sequence variation affecting the coding sequence
of PTPN11 (exons 1–15 and their ﬂanking intronic
stretches) was observed. On the contrary, 15 different
NF1 defects were identiﬁed in 16 of the 17 unrelated
subjects (table 2). Mutations cosegregated with the dis-
ease in the three families transmitting NFNS. Consis-
tently, none of the three lesions was observed in 1200
Italian control individuals. For sporadic cases with mu-
tations, parental DNA was available for patients NFNS-
1, NFNS-9, NFNS-10, and 128; no parent was identiﬁed
as carrying the mutation. A large deletion involving a
portion of the NF1 gene was observed in one subject
(NFNS-16). The deletion was suspected because of lack
of heterozygosity along the entire NF1 gene. Patient
NFNS-16 and both his parents were genotyped using
a battery of STR markers, either intragenic to NF1 or
ﬂanking the gene (see table 3), and loss of heterozygosity
due to loss of the maternal allele of marker 3′-NF1-1
(Lo´pez Correa et al. 1999), which is located 200 kb
downstream of the gene, was documented. STR results
were compatible with a partial deletion of 1.7 Mb of
the maternal chromosome, between markers D17S1849
(telomeric to exon 23-1) and D17S798 (telomeric to
NF1). The deletion was conﬁrmed by quantitative real-
time PCR performed on exon 25 of the gene (data not
shown; primers, probe, and experimental procedure are
available on request). In the remaining patient (NFNS-
17), no intragenic defect was identiﬁed. This individual
exhibited a heterozygous condition for ﬁve exonic and
intronic polymorphisms (IVS3, 28841GrA; Ex5,
702ArG; IVS10b, 1528-29insA; IVS29, 554719TrA;
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Table 2







NFNS-1 4b c.581TrG L194R Missense Novel
62c 11 17213ArG Splicing/truncating Purandare et al. 1994
NFNS-3 12a 1756delACTA Deletion/truncating Park and Pivnick 1998
NFNS-4 12b 1862delC Deletion/truncating Novel
69c 13 2153delA Deletion/truncating Novel
NFNS-6a 17 2970delAAT 991delMb Inframe deletion Carey et al. 1997
NFNS-7a 24 4243GrT E1415X Nonsense/truncating Fahsold et al. 2000
NFNS-8 24 4267ArG K1423Eb Missense Li et al. 1992
NFNS-9 24 4267ArG K1423Eb Missense Li et al. 1992
NFNS-10 25 4289ArC N1430T Missense Novel
NFNS-11 25 4294GrC V1432L Missense Novel
NFNS-12 25 4312delGAA 1438delEb Inframe deletion Baralle et al. 2003
70c 29 5339TrG L1780X Nonsense/truncating Fahsold et al. 2000
128 35 66411GrA Splicing/truncating Novel
NFNS-15c 45 7877delG Deletion/truncating Novel
NFNS-16 Partial NF1 gene deletiond Novel
NOTE.—Mutations affecting residues located within the GAP-related domain are shown in bold italics.
a From a family with three affected members.
b Mutations found to recur in NFNS.
c From a family with two affected members.
d Centromeric breakpoint maps between marker D17S1849 (intron 23-1) and exon 25, and telomeric breakpoint localizes
between markers 3′-NF1 (200 kb downstream of the NF1 gene) and D17S798 (1.6 Mb downstream of the NF1 gene).
Table 3
Markers on Chromosome 17q11.2
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
and IVS41, 7395-29GrA), which would not support oc-
currence of a deletion involving the entire NF1 gene. On
the whole, NF1 gene defects accounted for 16 (94.1%)
of the 17 NFNS cases included in the study.
NF1 intragenic lesions included nonsense and frame-
shift mutations as well as missense mutations and small
inframe deletions. According to the Human GeneMuta-
tion Database, 8 of the 15 defects were novel, whereas
the remaining 7 had been documented in patients with
NF1, either with or without NS features. Eight de-
fects, including four small out-of-frame deletions and
two splice-site and two nonsense mutations, were pre-
dicted to result in a truncated protein. Five mutations
of this group—17213ArG, 1756delACTA, 1862delC,
2153delA, and 4243GrT—would result in a protein
missing a portion of or the entire GAP-related domain,
which has a major role in controlling RAS function by
promoting conversion of active guanosine triphosphate
(GTP)–binding RAS to inactive guanosine diphosphate
(GDP)–binding RAS (Martin et al. 1990). Of note, four
of these mutations had been reported elsewhere in pa-
tients with NF1, none of whom exhibited features of
the NFNS condition. Six different missense mutations
or small inframe deletions were identiﬁed in seven pro-
bands. Remarkably, these lesions were not randomly dis-
tributed; the majority involved portions of the gene cod-
ing for two functional domains of the protein. Speciﬁ-
cally, ﬁve defects affected the GAP-related domain (ex-
ons 21–27a), the majority clustering in a short amino
acid stretch (residues 1423–1438) of this domain,whereas
the single-residue deletion affecting codon 991 was lo-
cated within the putative cysteine/serine–rich domain
(exons 11–17). Comparison with NF1 orthologs dem-
onstrated that all the affected residues were highly con-
served among vertebrates. Three of these mutations—
991delM, K1423E, and 1438delE—were reported else-
where (Li et al. 1992; Carey et al. 1997; Baralle et al.
2003). Among them, 991delM and 1438delE had been
documented in patients with NFNS (Carey et al. 1997;
Baralle et al. 2003), which indicates a genotype-pheno-
type correlation.
Because of relevant clustering of inframe mutations
within a small portion of the GAP-related domain, the
predicted spatial location and function of four affected
residues—K1423, N1430, V1432, and E1438—were
analyzed. To model the structure of the neuroﬁbromin/
RAS complex, RAS was docked to the structure of the
neuroﬁbromin GAP-related domain (Protein Data Bank
[PDB] code 1NF1), according to the experimental to-
pology of binding between the homologous p120GAP
and HRAS (PDB code 1WQ1). This model is in agree-
ment with the model of the neuroﬁbromin GRD/RAS
complex described by Scheffzek et al. (1998). As shown
in ﬁgure 2, all the affected residues lie at the interface
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Figure 2 Three-dimensional model showing location of residues affected by mutations in the neuroﬁbromin GAP-related domain/RAS
complex. Ribbon-like structures of neuroﬁbromin GAP-related domain and RAS are shown in green and yellow, respectively. The mutated
residues (Lys1423, Asn1430, Val1432, and Glu1438), the catalytic arginine ﬁnger (Arg1276), and GDP are represented by sticks and transparent
surfaces. Molecular alignment and representation were made with the programs SwissPdb Viewer v. 3.7 (Guex and Peitsch 1997) and PyMOL
(DeLano 2002), respectively.
of interaction between the GAP-related domain of neu-
roﬁbromin and RAS, close to the catalytic site of the
former. Such impressive clustering suggests that muta-
tions affecting these residues might impair the ability of
the neuroﬁbromin GAP-related domain in stimulation
of the GTPase activity of RAS, affecting either stability
of the neuroﬁbromin/RAS complex or neuroﬁbromin
catalytic activity. Structural data indicate that K1423 is
directly involved in the intermolecular interaction, since
it forms a salt bridge with residue D38 of RAS. Such
interaction is lost in the K1423E mutant, since the posi-
tive charge of the lysine is replaced with the negative
charge of a glutamic acid residue. Because of the elec-
trostatic repulsion between the two negatively charged
residues E1423 and D38, this mutation causes further
destabilization of the neuroﬁbromin/RAS complex. It has
been consistently demonstrated that the K1423E muta-
tion results in a dramatic reduction of GAP activity (Poul-
let et al. 1994). The structural reorganization caused by
the N1430T mutation might affect the local environ-
ment in proximity to residue R1276, which is known as
the arginine ﬁnger of the GAP-related domain and there-
fore might perturb the catalytic activity of the protein.
Disruptive effects on both substrate binding and catal-
ysis can also be expected for the substitution of V1432,
which lies on the surface of the GAP-related domain
in proximity to the arginine ﬁnger. In regard to the
1438delE mutation, E1438 is located in a region of
the domain with local negative electrostatic potential.
Loss of this ionizable negative group is predicted to cause
decreased repulsion to the negative surface of RAS,
which promotes an increased stability of the neuroﬁbro-
min/RAS complex. Other mutations (R1413G/K1436R,
N1430H, R1491K, and R1276G) with a similar per-
1098 Am. J. Hum. Genet. 77:1092–1101, 2005
turbing role on neuroﬁbromin binding to RAS were de-
scribed elsewhere (Morcos et al. 1996). Such an abnor-
mally increased stability of the complex would result in
the saturation of the GAP active site by lower RAS con-
centrations and, as a consequence, in decreased avail-
ability of the protein for stimulation of the GTPase ac-
tivity of further incoming RAS molecules.
Because of the wide clinical spectrum associated with
different NF1 mutations, we investigated possible geno-
type-phenotype relationships. Comparison with the data
reported by Fahsold et al. (2000) demonstrated a signif-
icantly higher prevalence of missense mutations and in-
frame deletions among patients with NFNS than among
individuals with NF1 (7/16 vs. 28/278; ;2x p 13.31
). Within the NFNS cohort, comparison ofPp .0003
the clinical features between patients carrying missense
mutations or inframe deletions and those with truncat-
ing mutations showed a preferential but not signiﬁcant
association, with a slightly increased risk of CHD (odds
ratio ; 95% CI 0.27–23.27; Fisher’s exact[OR]p 2.40
test one-tailed ). Among the families transmit-Pp .32
ting the trait, intrafamilial phenotypic variability was
evident. Patient NFNS-17, who apparently did not carry
any NF1 gene mutation or deletion, fulﬁlled the NF1
diagnostic criteria and presented with CLSs, axillary
freckling, learning difﬁculties, and the typical NS-asso-
ciated facial dysmorphisms, short stature, webbed neck,
and thoracic abnormality.
Because of the clinical overlap betweenNFNS andNS,
as well as the antagonistic modulatory function of neu-
roﬁbromin and SHP-2 in RAS signaling, we also inves-
tigated the possible contribution of NF1 gene lesions to
NS. One hundred unrelated patients with NS but no
symptoms of NF1 were screened for those exons (exons
11–27) and ﬂanking intronic sequences that represent
the major hotspot regions in patients with NFNS. All
subjects had been documented elsewhere to be negative
for mutations affecting the PTPN11 coding sequence
(Sarkozy et al. 2003; M.T., unpublished data). No NF1
pathogenetic mutation was detected.
As discussed elsewhere by Carey (1998), despite the
amount of work done and number of cases documented,
including a few families transmitting the trait, debate
still continues about the genetic cause and nosologic
entity of NFNS. It has been suggested that the NFNS
phenotype might represent the result of a chance associa-
tion of two common autosomal dominant disorders—
NF1 and NS—or that certain NF1 features in subjects
with NFNS might occur as a component of NS. In NS,
a similar association was documented for the occur-
rence of bony and soft-tissue giant cell lesions or CLSs,
as observed, respectively, in Noonan-like/multiple giant
cell lesion syndrome (NL/MGCLS [MIM 163955]) and
LEOPARD syndrome (LS [MIM 151100]). Indeed, both
NL/MGCLS and LS are caused by missense mutations
in the PTPN11 gene (Digilio et al. 2002; Legius et al.
2002; Tartaglia et al. 2002; Sarkozy et al. 2004; Lee et
al. 2005), which is mutated in a large percentage of
subjects with NS (Tartaglia and Gelb 2005). These con-
ditions can now be viewed as either a part of the NS
phenotypic spectrum (NL/MGCLS) or an allelic variant
of NS (LS).
In contrast, with one exception, no mutation affecting
PTPN11 has been identiﬁed in NFNS thus far (Baralle
et al. 2003; Bertola et al. 2005; present study), which
strongly supports the hypothesis that PTPN11 is not a
major disease gene contributing to or causing NFNS and
that NFNS and NS are distinct genetic disorders. Ac-
cordingly, large clinical studies of NS make no reference
to patients with neuroﬁbromas, which suggests that NF1
features do not occur frequently in classic NS (Sharland
et al. 1992). Coexistence of NS and NF1 features has
also been explained by consideration of certain NS signs
in subjects with NFNS as part of the phenotypic vari-
ability of NF1 or as a distinct and well-delineated con-
dition. Both these possibilities imply mutations in NF1
as a common molecular event underlying the condition.
However, in the former, one would expect both a number
of mutations shared with NF1 and a similar distribution.
In the latter, speciﬁc mutations not occurring (or rare)
in patients with NF1 would be expected. The identiﬁca-
tion of NF1 lesions in 16 of 17 subjects in the present
cohort provides evidence of a major role ofNF1 inNFNS.
With combination of the present and previous data, 18
distinct NF1 gene mutations have been described in 22
unrelated patients with NFNS (Carey et al. 1997; Baralle
et al. 2003; Castle et al. 2003; Bertola et al. 2005; present
study). These lesions include nonsense mutations, out-
of-frame deletions, insertions, or splicing mutations, as
well as missense mutations and small inframe deletions.
Among them, a statistically signiﬁcant incidence (42%)
of missense mutations and small inframe deletions is
observed. Remarkably, inframe defects account for a
considerably lower percentage (10%) of NF1 lesions
among patients with NF1 than among those with NFNS
(10/24 patients with NFNS studied [Carey et al. 1997;
Baralle et al. 2003; Castle et al. 2003; Bertola et al. 2005;
present study] vs. 28/278 patients with NF1 [Fahsold et
al. 2000]; ; ). In NFNS, most2x p 17.28 Pp .00003
(60%) of these inframe mutations cluster to the GAP-
related domain, which does not represent the major
(25%) mutational hotspot region formissensemutations
in patients with NF1 (6/10 patients with NFNS [Carey
et al. 1997; Baralle et al. 2003; Castle et al. 2003; Bertola
et al. 2005; present study] vs. 7/28 patients with NF1
[Fahsold et al. 2000]; Fisher’s exact test one-tailed Pp
)..055
A nonsigniﬁcant trend of association between inframe
mutations and CHD was also observed. Of note, two
of the mutations (991delM and 1438delE) we docu-
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mented in subjects with CHD had been associated with
CHD elsewhere (Carey et al. 1997; Castle et al. 2003).
In particular, 991delM had been associated with PVS in
patients with NFNS (Carey et al. 1997; present study)
and in patients withWatson syndrome, a condition char-
acterized by PVS, CLSs, and mental retardation and
caused by NF1 gene mutations (Tassabehji et al. 1993;
Castle et al. 2003), thus suggesting an independent re-
lationship between 991delM and PVS by the associated
phenotype
Remarkably, the clinical phenotype of patients re-
ported here is characterized by a peculiar presentation
of NF1 and NS features. Speciﬁcally, whereas plexiform
neuroﬁbroma was found only in a single patient, neither
pseudoarthrosis of the tibia nor NF1 gene mutation–
related tumors—other than neuroﬁbromas, optic gliomas,
and one neuroblastoma—occurred, either in pediatric
or in adult patients. These ﬁndings partly overlap with
the conclusions of Carey (1998), who reported the ab-
sence of Lisch nodules, the small number of dermal neu-
roﬁbromas, and the lack of internal tumors as distinct
features of NFNS. Among NS features, typical dysmor-
phisms were hypertelorism, ptosis, and low-set ears,
whereas short neck and stature and thoracic anomalies
were present in only half of the patients. The identiﬁca-
tion of speciﬁc NF1 alleles recurring in NFNS, the evi-
dence that these alleles cosegregate with the condition
in families, and the observation of a peculiar mutational
spectrum strongly suggest that the term “NFNS” does
characterize a phenotypic variant of NF1, which mani-
fests with a low incidence of plexiform neuroﬁbromas,
skeletal anomalies, and internal tumors, in association
with hypertelorism, ptosis, low-set ears, and CHDs.
However, it should be noted that some of the mutations
identiﬁed in patients with NFNS have also been reported
in NF1 without any feature suggestive of NS. From a
molecular point of view, the clinical overlap between
NFNS and NS is not surprising. Increasing evidence sup-
ports the hypothesis that NF1 and PTPN11 gene prod-
ucts—neuroﬁbromin and SHP-2 (a cytoplasmic protein
tyrosine phosphatase functioning as a transducer)—elicit
their modulatory role through a common pathway. In-
deed, whereas neuroﬁbromin stimulates the intrinsic GTP
hydrolysis of RAS proteins required for their functional
silencing, SHP-2 promotes their sustained activation.
The antagonistic function of neuroﬁbromin and SHP-2
on RAS-mediated transduction cascades modulates cell
response to several growth-factor and cytokine recep-
tors, which control a number of developmental processes
(Dasgupta and Gutmann 2003; Neel et al. 2003; Arun
and Gutmann 2004; Tartaglia et al. 2004b). Consistent
with the crucial role of neuroﬁbromin and SHP-2 in
modulating cell proliferation, children with NF1 or NS
are predisposed to distinct but overlapping spectra of
hematologic malignancies (Shannon et al. 1994; Side et
al. 1998; Tartaglia et al. 2003, 2004a, 2005). For both
NF1 and NS, deregulation of RAS signaling appears to
occur in a ligand-dependent manner, which suggests that
the differential contribution of these proteins to modula-
tion of transduction pathways elicited by distinct signals
might account for the phenotypic differences observed
in NF1/NFNS and NS.
On the whole, the present study provides the ﬁrst mo-
lecular evidence of a major role of NF1 mutations in
NFNS, emphasizing the extreme phenotypic variability
associated with lesions in the NF1 gene. We hypothesize
that mutations affecting regulatory portions of the gene
might also have a pathogenetic role in NFNS. Although
mutations affecting the NF1 promoter have not been re-
ported to date (Horan et al. 2000), lesions in other non-
coding portions are to be expected. Gross rearrangements
consistently comprise up to 5% of all NF1 mutations
documented in NF1 (Korf 1998; Upadhyaya and Cooper
1998; Kluwe et al. 2004). Even though the present data
do not allow exclusion of the possibility that NFNS is
genetically heterogeneous, they deﬁnitely exclude defects
in the coding sequence of the PTPN11 gene as a recur-
rent molecular event underlying NFNS. Similarly, the
recently reported chance occurrence ofmutations in both
NF1 and PTPN11 represent a rare event in NFNS, prob-
ably accounting for a minority of these cases (Bertola et
al. 2005). Finally, mutations in NF1 are unlikely to play
an important role in NS, which further supports the view
that NFNS is genetically distinct from NS.
Acknowledgments
We thank the patients and families who participated in this
study and the physicians who referred the subjects. This work
was supported in part by grants from the Italian Ministry of
Health (RC 2004 and RC 2005) and the Italian Ministry of
Education, University and Research (to B.D.) and Telethon-
Italy (GGP04172) and Programma di Collaborazione Italia-
USA/malattie rare (to M.T.).
Web Resources
The URLs for data presented herein are as follows:
Human Gene Mutation Database, http://archive.uwcm.ac.uk/
uwcm/mg/hgmd0.html
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for NFNS, NF1, NS, PTPN11,
NL/MGCLS, and LS)
PDB, http://www.rcsb.org/pdb/
UCSC Genome Browser, http://genome.ucsc.edu/
References
Abuelo DN, Meryash DL (1988) Neuroﬁbromatosis with fully
expressed Noonan syndrome. Am J Med Genet 29:937–941
Allanson JE (1987) Noonan syndrome. J Med Genet 24:9–13
1100 Am. J. Hum. Genet. 77:1092–1101, 2005
Allanson JE, Hall JG, Van Allen MI (1985) Noonan phenotype
associated with neuroﬁbromatosis. Am J Med Genet 21:457–
462
Arun D, Gutmann DH (2004) Recent advances in neuroﬁbro-
matosis type 1. Curr Opin Neurol 17:101–105
Bahuau M, Flintoff W, Assouline B, Lyonnet S, Le Merrer M,
Prieur M, Guilloud-Bataille M, Feingold N, Munnich A, Vi-
daud M, Vidaud D (1996) Exclusion of allelism of Noonan
syndrome and neuroﬁbromatosis-type 1 in a large family with
Noonan syndrome-neuroﬁbromatosis association. Am J Med
Genet 66:347–355
Bahuau M, Houdayer C, Assouline B, Blanchet-Bardon C, Le
Merrer M, Lyonnet S, Giraud S, Recan D, Lakhdar H, Vi-
daud M, Vidaud D (1998) Novel recurrent nonsense muta-
tion causing neuroﬁbromatosis type 1 (NF1) in a family seg-
regating both NF1 and Noonan syndrome. Am J Med Genet
75:265–272
Baralle D, Mattocks C, Kalidas K, Elmslie F, Whittaker J, Lees
M, Ragge N, Patton MA, Winter R, ffrench-Constant C
(2003) Different mutations in the NF1 gene are associated
with neuroﬁbromatosis-Noonan syndrome (NFNS). Am J
Med Genet 119:1–8
Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen
L, Gelb BD, Kim CA, Krieger JE (2005) Neuroﬁbromatosis-
Noonan syndrome: molecular evidence of the concurrence
of both disorders in a patient. Am J Med Genet A 136:242–
245
Carey JC (1998) Neuroﬁbromatosis-Noonan syndrome. Am J
Med Genet 75:263–264
Carey JC, Stevenson DA, Ota M, Neil S, Viskochil DH (1997)
Is there an Noonan syndrome: part 2: documentation of the
clinical and molecular aspects of an important family. Proc
Greenwood Genet Center 17:52–53
Castle B, Baser ME, Huson SM, Cooper DN, Upadhyaya M
(2003) Evaluation of genotype-phenotype correlations in
neuroﬁbromatosis type 1. J Med Genet 40:109
Colley A, Donnai D, Evans DGR (1996) Neuroﬁbromatosis/
Noonan phenotype: a variable feature of type 1 neuroﬁbro-
matosis. Clin Gen 49:59–64
Dasgupta B, Gutmann DH (2003) Neuroﬁbromatosis 1: clos-
ing the GAP between mice and men. Curr Opin Genet Dev
13:20–27
De Luca A, Buccino A, Gianni D, Mangino M, Giustini S,
Richetta A, Divona L, Calvieri S, Mingarelli R, Dallapiccola
B (2003) NF1 gene analysis based on DHPLC. Hum Mutat
21:171–172
De Luca A, Schirinzi A, Buccino A, Bottillo I, Sinibaldi L, Tor-
rente I, Ciavarella A, Dottorini T, Porciello R, Giustini S,
Calvieri S, Dallapiccola B (2004) Novel and recurrent muta-
tions in the NF1 gene in Italian patients with neuroﬁbroma-
tosis type 1. Hum Mutat 23:629
DeLano WL (2002) Unraveling hot spots in binding interfaces:
progress and challenges. Curr Opin Struct Biol 12:14–20
Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T,
Marino B, Pizzuti A, Dallapiccola B (2002) Grouping of
multiple-lentigines/LEOPARD and Noonan syndromes on
the PTPN11 gene. Am J Hum Genet 71:389–394
Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Ku¨-
cu¨kceylan N, Abdel-Nour M, Gewies A, Peters H, Kaufmann
D, Buske A, Tinschert S, Nu¨rnberg P (2000) Minor lesion
mutational spectrum of the entire NF1 gene does not explain
its high mutability but points to a functional domain up-
stream of the GAP-related domain. Am J Hum Genet 66:
790–818
Guex N, Peitsch (1997) MC SWISS-MODEL and the Swiss-
PdbViewer: an environment for comparative protein mod-
eling. Electrophoresis 18:2714–2723
Gutmann DH, Aylsworth A, Carey JC, Korf B,Marks J, Pyeritz
RE, Rubenstein A, Viskochil D (1997) The diagnostic evalua-
tion and multidisciplinary management of neuroﬁbroma-
tosis 1 and neuroﬁbromatosis 2. JAMA 278:51–57
Horan MP, Cooper DN, Upadhyaya M (2000) Hypermethy-
lation of the neuroﬁbromatosis type 1 (NF1) gene promoter
is not a common event in the inactivation of the NF1 gene
in NF1-speciﬁc tumours. Hum Genet 107:33–39
Jongmans M, Sistermans EA, Rikken A, Nillesen WM, Tam-
minga R, Patton M, Maier EM, Tartaglia M, Noordam K,
van der Burgt I (2005) Genotypic and phenotypic charac-
terization of Noonan syndrome: new data and review of the
literature. Am J Med Genet A 134:165–170
Kaplan P, Rosenblatt B (1985) A distinctive facial appearance
in neuroﬁbromatosis von Recklinghausen. Am J Med Genet
21:463–470
Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-
Sawatzki H, Mautner VF (2004) Screening 500 unselected
neuroﬁbromatosis 1 patients for deletions of the NF1 gene.
Hum Mutat 23:111–116
Korf BR (1998) TheNF1Genetic Analysis Consortium. In: Upa-
dhyayaM, Cooper DN (eds) Neuroﬁbromatosis type 1: from
genotype to phenotype. BIOS Scientiﬁc, Oxford, United
Kingdom, pp 57–62
Lee JS, Tartaglia M, Gelb BD, Fridrich K, Sachs S, Stratakis
CA, Muenke M, Robey PG, Collins MT, Slavotinek A (2005)
Phenotypic and genotypic characterisation of Noonan-like/
multiple giant cell lesion syndrome. J Med Genet 42:e11
Legius E, Schrander-Stumpel C, Schollen E, Pulles-Heintzber-
ger C, Gewillig M, Fryns JP (2002) PTPN11 mutations in
LEOPARD syndrome. J Med Genet 39:571–574
Li Y, Bollag G, Clark R, Stevens J, Conroy L, Fults D, Ward
K, Freidman E, Samowits W, Robertson M, Bradley P, Mc-
Cormick F, White R, Cawthon R (1992) Somatic mutations
in the neuroﬁbromatosis type 1 gene in human tumours. Cell
69:275–281
Lo´pez Correa C, Brems H, La´zaro C, Estivill X, Clementi M,
Mason S, Rutkowski JL, Marynen P, Legius E (1999) Mo-
lecular studies in 20 submicroscopic neuroﬁbromatosis type
1 gene deletions. Hum Mutat 14:387–393
Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ,
Haubruck H, Conroy L, Clark R, O’Connell P, Cawthon
RM, Innis MA, McCormick F (1990) The GAP-related do-
main of the neuroﬁbromatosis type 1 gene product interacts
with ras p21. Cell 63:843–849
Meinecke P (1987) Evidence that the “neuroﬁbromatosis-Noo-
nan syndrome” is a variant of von Recklinghausen neuro-
ﬁbromatosis. Am J Med Genet 26:741–745
Mendez HM (1985) The neuroﬁbromatosis-Noonan syndrome.
Am J Med Genet 21:471–476
Morcos P, Thapar N, Tusneem N, Stacey D, Tamanoi F (1996)
Reports 1101
Identiﬁcation of neuroﬁbromin mutants that exhibit allele
speciﬁcity or increased Ras afﬁnity resulting in suppression
of activated ras alleles. Mol Cell Biol 16:2496–2503
Neel BG, GuH, Pao L (2003) The ‘Shp’ing news: SH2 domain-
containing tyrosine phosphatases in cell signaling. Trends
Biochem Sci 28:284–293
Opitz JM, Weaver DD (1985) The neuroﬁbromatosis-Noonan
syndrome. Am J Med Genet 21:477–490
Park VM, Pivnick EK (1998) Neuroﬁbromatosis type 1 (NF1):
a protein truncation assay yielding identiﬁcation of muta-
tions in 73% of patients. J Med Genet 35:813–820
Poullet P, Lin B, Esson K, Tamanoi F (1994) Functional sig-
niﬁcance of lysine 1423 of neuroﬁbromin and characteriza-
tion of a second site suppressor which rescues mutations at
this residue and suppresses RAS2Val-19-activated pheno-
types. Mol Cell Biol 14:815–821
Purandare SM, Lanyon WG, Connor JM (1994) Characterisa-
tion of inherited and sporadic mutations in neuroﬁbroma-
tosis type-1. Hum Mol Genet 3:1109–1115
Quattrin T, McPherson E, Putnam T (1987) Vertical transmis-
sion of the neuroﬁbromatosis/Noonan syndrome. Am JMed
Genet 26:645–649
Riccardi VM (1992) Neuroﬁbromatosis: phenotype, natural
history, and pathogenesis, 2nd ed. John Hopkins University,
Baltimore
Sarkozy A, Conti E, Digilio MC, Marino B, Morini E, Pacileo
G, Wilson M, Calabro R, Pizzuti A, Dallapiccola B (2004)
Clinical and molecular analysis of 30 patients with multiple
lentigines LEOPARD syndrome. J Med Genet 41:e68
Sarkozy A, Conti E, Seripa D, Digilio MC, Grifone N, Tandoi
C, Fazio VM, Di Ciommo V, Marino B, Pizzuti A, Dallap-
iccola B (2003) Correlation between PTPN11 gene muta-
tions and congenital heart defects in Noonan and LEOPARD
syndromes. J Med Genet 40:704–708
Saul RA (1985) Noonan syndrome in a patient with hyper-
plasia of the myenteric plexuses and neuroﬁbromatosis. Am
J Med Genet 21:491–492
Scheffzek K, Ahmadian MR, Wiesmuller L, Kabsch W, Stege
P, Schmitz F, Wittinghofer A (1998) Structural analysis of
the GAP-related domain from neuroﬁbromin and its impli-
cations. EMBO J 17:4313–4327
Shannon KM, O’Connell P, Martin GA, Paderanga D, Olson
K, Dinndorf P, McCormick F (1994) Loss of the normal
NF1 allele from the bone marrow of children with type 1
neuroﬁbromatosis and malignant myeloid disorders. N Engl
J Med 330:597–601
Sharland M, Burch M, McKenna WM, Paton MA (1992) A
clinical study of Noonan syndrome. Arch Dis Child 67:178–
183
Shuper A, Mukamel M, Mimouni M, Steinherz R (1987) Noo-
nan’s syndrome and neuroﬁbromatosis. Arch Dis Child 62:
196–198
Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Cas-
tleberry RP, Shannon KM (1998)Mutations of the NF1 gene
in children with juvenile myelomonocytic leukemia without
clinical evidence of neuroﬁbromatosis, type 1. Blood 92:267–
272
Stern HJ, Saal HM, Lee JS, Fain PR, Goldgar DE, Rosenbaum
KN, Barker DF (1992) Clinical variability of type 1 neu-
roﬁbromatosis: is there a neuroﬁbromatosis-Noonan syn-
drome? J Med Genet 29:184–187
Stumpf DA, Alksne JF, Annegers JF, Brown SS, Conneally PM,
Housman D, Leppert MF, Miller JP, Moss ML, Pileggi AJ,
Rapin I, Strohman RC, Swanson LW, Zimmerman A (1988)
Neuroﬁbromatosis: conference statement. Arch Neurol 45:
575–578
Tartaglia M, Gelb BD (2005) Noonan syndrome and related
disorders: genetics and pathogenesis. Annu Rev Genomics
Hum Genet 6:45–68
Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der
Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kuch-
erlapati RS, Jeffery S, Patton MA, Gelb BD (2002) PTPN11
mutations in Noonan syndrome: molecular spectrum, geno-
type-phenotype correlation, and phenotypic heterogeneity.
Am J Hum Genet 70:1555–1563
Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone
I, Spinelli M, Palmi C, Carta C, Pession A, Arico M, Masera
G, Basso G, Sorcini M, Gelb BD, Biondi A (2004a) Genetic
evidence for lineage-related and differentiation stage-related
contribution of somatic PTPN11 mutations to leukemogen-
esis in childhood acute leukemia. Blood 104:307–313
Tartaglia M, Martinelli S, Iavarone I, Cazzaniga G, Spinelli
M, Giarin E, Petrangeli V, Carta C, Masetti R, Arico M,
Locatelli F, Basso G, Sorcini M, Pession A, Biondi A (2005)
Somatic PTPN11 mutations in childhood acute myeloid leu-
kaemia. Br J Haematol 129:333–339
Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner
HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery
S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD (2001)
Mutations in PTPN11, encoding the protein tyrosine phos-
phatase SHP-2, cause Noonan syndrome. Nat Genet 29:465–
468
Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J,
Jung A, Hahlen K, Hasle H, Licht JD, Gelb BD (2003) So-
matic mutations in PTPN11 in juvenile myelomonocytic leu-
kemia, myelodysplastic syndromes and acute myeloid leuke-
mia. Nat Genet 34:148–150
Tartaglia M, Niemeyer CM, Shannon KM, Loh ML (2004b)
SHP-2 and myeloid malignancies. Curr Opin Hematol 11:
44–50
Tassabehji M, Strachan T, Sharland M, Colley A, Donnai D,
Harris R, Thakker N (1993) Tandem duplication within a
neuroﬁbromatosis type 1 (NF1) gene exon in a family with
features of Watson syndrome and Noonan syndrome. Am
J Hum Genet 53:90–95
Upadhyaya M, Cooper DN (1998) The mutational spectrum
in neuroﬁbromatosis type 1 and its underlying mechanisms.
In: Upadhyaya M, Cooper DN (eds) Neuroﬁbromatosis type
1: from genotype to phenotype. BIOS Scientiﬁc, Oxford,
United Kingdom, pp 65–82
van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel
B, Mariman E (1994) Clinical and molecular studies in a
large Dutch family with Noonan syndrome. Am J Med Ge-
net 53:187–191
Xu G, O’Connell P, Viskochil D, Cawthorn R, Robertson M,
Culver M, Dunn D, Stevens J, Gesteland R, White R, Weiss
R (1990) The neuroﬁbromatosis type 1 gene encodes a pro-
tein related to GAP. Cell 62:599–608
